A Phase 1/2 Randomized, Double-Blind, Placebo-Controlled Trial of Multiple Sublingual 5-MeO-DMT Microdoses for Reducing Anxiety and/or Depression in Patients With Mild Cognitive Impairment.
Latest Information Update: 14 Apr 2025
At a glance
- Drugs 5 Methoxy N N Dimethyltryptamine (Primary)
- Indications Alzheimer's disease; Anxiety; Mild cognitive impairment
- Focus Therapeutic Use
- Sponsors Biomind Labs
Most Recent Events
- 09 Apr 2025 Status changed from active, no longer recruiting to completed.
- 13 Feb 2025 New trial record